Patients with advanced Hodgkin's lymphoma who were in complete remission after chemotherapy were assigned to receive involved-field radiotherapy or no further treatment. After a median follow-up of ...more than six years, survival was similar in the two groups.
The outcome of treatment for advanced Hodgkin's lymphoma has improved dramatically over the past two decades. Cure rates of more than 70 percent are now possible
1
–
10
with a hybrid regimen of mechlorethamine, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (MOPP-ABV); a regimen of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD); or a regimen of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP).
The potential role of radiotherapy after the completion of chemotherapy in patients with advanced Hodgkin's lymphoma stems from the observations that relapses usually occur at initially involved sites and that radiotherapy lowers the rates of recurrence.
11
The . . .
PDF
